

Docket No. 275596US96X PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Haruo SUGIYAMA, et al.

SERIAL NO: 10/517,600

GAU:

FILED: December 13, 2004

EXAMINER:

FOR: HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

James J. Kelly, Ph.D.
Registration No. 41,504

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



Docket No.: 275596US96X PCT Serial No.: 10/517,600

Inventor: Haruo SUGIYAMA, et al.

Filing Date: December 13, 2004

Group:

LIST OF RELATED CASES

<u>Examiner Initial</u>	<u>Docket No.</u>	<u>Serial or Patent Number</u>	<u>Filing or Issue Date</u>	<u>Patent App. Publication No.</u>	<u>Inventor or Applicant</u>
	275596US96XPCT*	10/517,600	12/13/04		SUGIYAMA, et al.
	283121US0PCT	10/527,692	03/11/05		SUGIYAMA
	283124US0XPCT	10/528,360	03/18/05		SUGIYAMA, et al.
	276146US40DIV	11/196,459	08/04/05	US2005/0266014 A1	SUGIYAMA, et al.
	276141US40CONT	11/196,452	08/04/05		SUGIYAMA, et al.
	283125US0XPCT	10/541,821	07/11/05		SUGIYAMA, et al.

Examiner

Date Considered

*Present Application; listed for information
NFO/hah

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 275596US96X PCT	SERIAL NO. 10/517,600	
LIST OF REFERENCES CITED BY APPLICANT DEC 29 2005 PATENT & TRADEMARK OFFICE		APPLICANT Haruo SUGIYAMA, et al.				
		FILING DATE December 13, 2004		GROUP		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
	AA	2005/0266014	12/01/05	SUGIYAMA ET AL		
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)						
	AW					
	AX					
	AY					
	AZ				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered		

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.